LWLi Wang

Li Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li Wang has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Xi Shen

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, PR China

    17 shared publications
  • Yanping Kuang

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    11 shared publications
  • Yali Liu

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, PR China

    10 shared publications
  • Yunhan Nie

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, PR China

    10 shared publications
  • Wenya Guo

    Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, PR China

    8 shared publications
  • Yuqi Zeng

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, PR China

    8 shared publications

Latest Publications

  • Open Access

    Progesterone prevents premature LH surge/ovulation by remodeling GnRH neuron activity

    by Xi Shen, Yuting Huang, Lin Qiu, Haoran Chen, Yali Liu, Yunhan Nie, Yuqi Zeng, Yanping Kuang, Li Wang

  • Open Access

    Hypothalamic lncRNA Synage prevents age-related sperm quality decline by suppressing A-type potassium currents in GnRH neurons

    by Fei Wang, Mengyi Zhang, Mengtian Wang, Shuhan Tian, Qian Bian, Yaohui He, Shuiqiao Yuan, Qinghua Shi, Wen Liu, Jun Xiao, et al.

    Age-related decline in male fertility, including diminished sperm quality, poses significant risks to offspring health and is exacerbated by modern trends toward delayed parenthood. Focusing on the hypothalamus–pituitary–testis axis, which governs hormonal control of male reproduction, we identified Synage , a long noncoding RNA expressed in the hypothalamic medial preoptic area (mPOA). We found that Synage expression in gonadotropin-releasing hormone (GnRH) neurons decreases with age, correlating with reduced sperm quality and male fertility. mPOA-targeted Synage _B (brain-specific isoform) supplementation increases serum testosterone and improves sperm count and progressive motility in 12-mo-old mice. Conversely, conditional deletion of Synage in GnRH neurons in young mice reduces GnRH neuron firing, decreases serum LH and testosterone levels, impaires sperm quality, and reduces male fertility. Mechanistically, Synage interacts with the heat shock protein HSPA8 and stabilizes the HSPA8–KCHIP4 interaction. Synage loss increases KCHIP4 abundance and its association with the Kv4.2 channel, promoting Kv4.2 membrane recruitment and enhancing A-type potassium currents ( I A ), thereby reducing GnRH neuronal excitability. Consistent with this model, GnRH neurons from 12-mo-old mice also exhibit reduced excitability. Together, these findings support a role for age-dependent Synage loss in reproductive decline, at least in part through dysregulation of the HSPA8–KCHIP4–Kv4.2 pathway and reduced GnRH neuron excitability. These findings identify Synage as a candidate regulator of reproductive aging and motivate further investigation of its translational potential.

  • Open Access

    Risk factors and treatment strategies for live birth in women with high BMI undergoing ART

    by Yunhan Nie, Yuting Huang, Zhe Kuang, Mingru Yin, Xi Shen, Yali Liu, Hongyuan Gao, Hui Long, Li Wang

    Women with a high BMI represent a growing and challenging population in assisted reproductive technology, as known impairments to treatment outcomes. However, the specific risk factors contributing to recurrent live birth failure and the potential treatment strategies to overcome initial setbacks in this group remain unclear. In this large-scale retrospective cohort study (2010-2023), 10,581 women were stratified into overweight (BMI 24-27.99 kg/m ², n = 8,350) and obese (BMI ≥ 28 kg/m ², n = 2,231) groups. Two-tiered analysis used generalized linear mixed models (GLMMs): (1) multilevel multinomial logistic regression to identify risk factors for recurrent failure; and (2) multilevel logistic regression to evaluate treatment strategies following initial failed frozen embryo transfers (FETs). In the risk factor analysis, women with recurrent failure were older (33-35 years) and had poorer ovarian reserve (AFC ~ 7-9) than those with live birth (~ 31 years, AFC ~ 12-15). Multivariable analysis confirmed advanced maternal age as a key risk factor (aOR = 1.98, 95% CI: 1.85-2.12). Higher hMG dose per mature follicle increased single-failure risk versus < 350 IU: for 350-500 IU, aOR = 1.43, 95% CI: 1.16-1.76 (overweight) and 1.66, 95% CI: 1.14-2.43 (obese); for > 500 IU, aOR = 1.77, 95% CI: 1.45-2.16 (overweight) and 1.58, 95% CI: 1.1-2.25 (obese). Switching to PPOS-versus mild stimulation-was associated with a lower risk of continued failure (aOR = 0.54, 95% CI: 0.40-0.74). Propensity score matching confirmed PPOS positively related with embryological yields; live birth rates were higher but not statistically significant (45.7% vs. 43.7%). Blastocyst transfer (aOR = 0.54, 95% CI: 0.42-0.69) was associated with a lower risk of continued failure. This study is, to our knowledge, one of the largest studies to systematically distinguish non-modifiable baseline risks (age and AFC) from modifiable ART-related factors (stimulation protocol, hMG dosage, and embryo transfer policy) for recurrent failure in a large population with high-BMI. This distinction provides preliminary insights to implement risk-stratified clinical approaches, especially for lower-risk patients. These approaches include adopting PPOS, optimizing gonadotropin dosage, and cautiously individualizing embryo transfer strategy, which may serve as potential therapeutic alternatives after initial setbacks.

  • Open Access

    Obesity inhibits hypothalamic activation and luteinizing hormone dynamics through Sox-2-dependent demyelination

    by Yunhan Nie, Wenya Guo, Lin Qiu, Jialiang Liu, Zhe Kuang, Jiqiang Si, Yuqi Zeng, Xi Shen, Yali Liu, Li Wang

  • Orosomucoid 2 improves reproductive phenotypes in a mouse model of PCOS induced by letrozole under high-fat diet conditions

    by Qiuyu Xu, Shuwen Qiu, Li Wang, Yali Liu, Yan Lu, Ling Wu, Jie Zhang

    Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder among women of reproductive age. It is characterized by excess androgens, anovulation, and polycystic ovarian morphology, and is often accompanied by obesity, insulin resistance, and glucose metabolism abnormalities. Although PCOS is a complex disease with diverse and uncertain etiologies, metabolic dysfunction and adipose tissue abnormalities are critical components in its pathology. Previous studies have demonstrated that letrozole exposure combined with high-fat diet treatment in female mice produced key endocrine and metabolic features of PCOS, including elevated testosterone levels, anovulation, and adipocyte hypertrophy. Orosomucoid 2 (ORM2), an acute-phase protein predominantly secreted by hepatocytes, plays a regulatory role in metabolic balance and gut microbiota composition. This study aimed to investigate the effects of ORM2 levels on the metabolic and endocrine dysregulations associated with letrozole-induced PCOS in female mice. We established a letrozole-induced PCOS by treating mice with Let+HFD (letrozole and high-fat diet) for 5 weeks. Our findings revealed that compared to control females receiving placebo and high-fat diet treatment, females treated with Let+HFD exhibited significantly reduced hepatic Orm2 expression. Furthermore, Orm2 knockout mice subjected to Let+HFD treatment developed more severe ovarian pathology, higher testosterone levels, hepatocyte hypertrophy, and reduced Ucp1 expression in white adipose tissue compared to wild-type mice. Conversely, supplementation with recombinant ORM2 protein in females under Let+HFD treatment resulted in improved ovarian morphology, reduced hepatocyte cell size, and enhanced Ucp1 expression in white adipose tissue. Overall, this research identifies ORM2 as a promising therapeutic target for PCOS treatment.


  • Open Access

    Dual rescue mission: P-G3 dendrimer addresses ovarian and neuroendocrine roots of obesity-linked subfertility

    by Yunhan Nie, Zhe Kuang, Jiqiang Si, Yuting Huang, Yuqi Zeng, Xi Shen, Yali Liu, Lin Qiu, Li Wang


  • Open Access

    A valuable predictive model for optimizing the timing of oocyte retrieval: a retrospective analysis of oocyte retrieval time in 49,961 oocyte pickup (OPU) cycles

    by Yuting Huang, Zhe Kuang, Xi Shen, Yunhan Nie, Yuqi Zeng, Yali Liu, Li Wang

    In clinical practice, scheduling oocyte retrieval is a challenging issue that requires comprehensive consideration of factors such as the woman's age, ovarian response, hormone levels and other variables. Moreover, there is currently no consensus on how to effectively consider these factors and their weights in order to optimize the scheduling of oocyte retrieval for obtaining more mature oocytes. To effectively identify the key determinants of oocyte retrieval time through an extensive analysis of retrospective clinical data, and to develop a valuable predictive model for optimizing the timing of oocyte retrieval in assisted reproductive technology (ART). This retrospective study included 49,961 oocyte pickup (OPU) cycles, as well as 5567 subsequent ET cycles and 45,198 FET cycles between January 2010 and August 2024. Multiple linear regression (MLR) and directed acyclic graphs (DAG) were employed to identify the key determinants associated with oocyte retrieval time. Oocyte pickup (OPU) cycles achieving a minimum of 70% oocyte retrieval rate and 80% oocyte maturation rate, indicating well-organized timing of oocyte retrieval, were assigned to Group 1, while the remaining cycles were assigned to Group 2. The data from Group 1 was randomly divided into training and validation sets using the "sample" function in R software. The training set data was utilized to develop a predictive model for oocyte retrieval time based on former identified determinants using the "lm" function in R software. Subsequently, the performance of this model was evaluated and visualised using the "performance" and "plot" function, and further validated with the validation set from Group 1 as well as the data from Group 2. Female age, AFC, COH protocol, number of follicles > 14 mm in diameter on the day of trigger, and hormone levels on the day of trigger (including E2, P, and LH) were key determinants for the timing of oocyte retrieval. A valuable predictive formula for determining the optimal timing of oocyte retrieval has been formulated and validated: 37.43-0.02219*Female age + 0.01383*AFC + 0.00006* E2 level on the trigger day-0.00939*P level on the trigger day-0.05194*LH level on the trigger day + 0.01497*Number of follicles > 14 mm in diameter on the trigger day + β (β = 0.0000 in Short agonist protocol, β = -0.3320 in PPOS protocol, β = 0.8361 in GnRH antagonist protocol, β = -1.2280 in Mild stimulation protocol, β = 0.4160 in Long agonist protocol). The female age, antral follicle count (AFC), controlled ovarian hyperstimulation (COH) protocol, number of follicles measuring > 14 mm in diameter on the trigger day, as well as hormone levels including E2, P, and LH on the trigger day are crucial factors influencing oocyte retrieval time. A robust predictive model for oocyte retrieval time was successfully developed from these factors and validated within a well-organized timing group for oocyte retrieval (oocyte retrieval rate ≥ 70% and oocyte maturation rate ≥ 80%).


  • Open Access

    In-vivo properties and functional subtypes of gonadotropin-releasing hormone neurons

    by Yali Liu, Xi Shen, Yuqi Zeng, Yunhan Nie, Jiamin Xu, Allan E. Herbison, Yanping Kuang, Li Wang


  • Open Access

    Clomiphene citrate reduces premature LH surge in obese women during controlled ovarian stimulation: a retrospective cohort study

    by Yuqi Zeng, Yuting Huang, Yali Liu, Xi Shen, Yunhan Nie, Li Wang, Yanping Kuang

    Background: Clomiphene citrate effectively suppressed the negative feedback of estrogen on the hypothalamus and induces premature luteinizing hormone (LH) surge during controlled ovulation stimulation, while obese women often have impaired hypothalamic-pituitary function. This study aimed to investigate whether the utilization of clomiphene citrate for controlled ovulation stimulation in obese women can effectively decrease the likelihood of premature LH surge.Methods: A retrospective study was conducted on women under the age of 38 with normal menstrual cycles and ovarian reserve who underwent controlled ovulation stimulation (COH) using clomiphene citrate. The participants were categorized by the Asian body mass index (BMI) classification. The dynamic reproductive endocrinological profiles during COH, especially the probability of serum LH concentration exceeding 10 IU/L, as well as the outcomes related to the embryo development and pregnancy, were compared among three BMI groups.Results: The basal levels of LH exhibited a significant reduction in overweight and obese women (p<0.001). Additionally, there was a significant decrease in the incidence of LH concentration exceeding 10 IU/L during controlled ovulation stimulation among overweight and obese women (7.19% vs 3.62% vs2.27%, p<0.05). Moreover, there were no significant differences observed among the three BMI groups regarding embryo transfer numbers, implantation, pregnancy or live birth rates.Conclusions: In obese women, clomiphene citrate effectively controlled LH levels, resulting a low prevalence of premature LH surge compared to patients with normal weight. This evidence contributes to a safer and more effective treatment for infertility in obese individuals.


  • Open Access

    The PPOS protocol mitigates the detrimental effects of high BMI on embryo and clinical pregnancy outcomes

    by Xi Shen, Menghui Li, Yunhan Nie, Jiqiang Si, Yali Liu, Tiantian Wang, Hongyuan Gao, Kaibo Lin, Li Wang

    The impact of high body mass index (BMI) on embryo and pregnancy outcomes in women using the PPOS (progestin-primed ovarian stimulation) protocol during their first frozen embryo transfer (FET) cycles is not clear. This study is to investigate the impact of BMI on oocyte, embryo, and pregnancy outcomes in patients who underwent the PPOS protocol. This retrospective study included the first FET cycle of 22,392 patients following the PPOS protocol. The impact of BMI on oocyte and pregnancy outcomes was assessed across different BMI groups, using direct acyclic graph to determine covariates, followed by the application of multiple linear and logistic regressions to further validate this influence. The high BMI groups exhibited a higher number of oocytes; however, no significant differences were observed in good-quality embryos, clinical pregnancy rate, and implantation rate. Nevertheless, the high BMI groups demonstrated a significantly elevated miscarriage rate (9.9% vs. 12.2% vs. 15.7% vs. 18.3%, P < 0.001), particularly in late miscarriages, resulting in lower live birth rates (LBR, 41.1% vs. 40.2% vs. 37.3% vs. 36.2%, P = 0.001). These findings were further confirmed through multiple liner and logistic regression analyses. Additionally, several maternal factors showed significant associations with adjusted odds ratios for early miscarriage. However, women with a BMI ≥ 24 who underwent hormone replacement cycle or hMG late stimulation protocol for endometrial preparation experienced an increased risk of late miscarriage. By utilizing the PPOS protocol, women with a high BMI exhibit comparable outcomes in terms of embryo and clinical pregnancies. However, an elevated BMI is associated with an increased risk of miscarriage, leading to a lower LBR. Adopting appropriate endometrial preparation protocols such as natural cycles and letrozole stimulation cycles may potentially offer benefits in reducing miscarriages.